ARTICLE | Clinical News
Idec Phase I results
March 15, 2000 8:00 AM UTC
IDPH said its IDEC-114 primatized anti- B7-1 (anti- CD80) monoclonal antibody, to treat moderate to severe psoriasis, showed a favorable safety profile with preliminary findings of clinical activity. ...